UBS downgraded Charles River (CRL) to Neutral from Buy with a price target of $185, down from $250. The Neutral rating reflects a view that the

William Blair downgraded Charles River Laboratories to market perform from outperform citing a likely decline in early-stage R&D spending from large pharmaceutical companies. Analysts Max Smock and Christine Rains said that they are concerned about the near-term outlook for the contract research organization "given our view that in light of the